FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216541074> ?p ?o ?g. }

• W3216541074 endingPage "165" @default.
• W3216541074 startingPage "158" @default.
• W3216541074 abstract "Haematoma growth is common early after intracerebral haemorrhage (ICH), and is a key determinant of outcome. Tranexamic acid, a widely available antifibrinolytic agent with an excellent safety profile, may reduce haematoma growth.Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units (STOP-MSU) is a phase II double-blind, randomised, placebo-controlled, multicentre, international investigator-led clinical trial, conducted within the estimand statistical framework.In patients with spontaneous ICH, treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.A sample size of 180 patients (90 in each arm) would be required to detect an absolute difference in the primary outcome of 20% (placebo 39% vs treatment 19%) under a two-tailed significance level of 0.05. An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Participants will receive 1 g intravenous tranexamic acid over 10 min, followed by 1 g intravenous tranexamic acid over 8 hours; or matching placebo.The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours, defined as either ≥33% relative increase or ≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.We describe the rationale and protocol of STOP-MSU, a phase II trial of tranexamic acid in patients with ICH within 2 hours from onset, based in participating mobile stroke units and emergency departments." @default.
• W3216541074 created "2021-12-06" @default.
• W3216541074 creator A5002655528 @default.
• W3216541074 creator A5003098121 @default.
• W3216541074 creator A5010123141 @default.
• W3216541074 creator A5013597842 @default.
• W3216541074 creator A5015105927 @default.
• W3216541074 creator A5016876268 @default.
• W3216541074 creator A5018029121 @default.
• W3216541074 creator A5018605276 @default.
• W3216541074 creator A5019133381 @default.
• W3216541074 creator A5020883910 @default.
• W3216541074 creator A5023847142 @default.
• W3216541074 creator A5024784197 @default.
• W3216541074 creator A5025718857 @default.
• W3216541074 creator A5028774301 @default.
• W3216541074 creator A5034143823 @default.
• W3216541074 creator A5035996984 @default.
• W3216541074 creator A5036319128 @default.
• W3216541074 creator A5037141792 @default.
• W3216541074 creator A5037210013 @default.
• W3216541074 creator A5038007169 @default.
• W3216541074 creator A5039358787 @default.
• W3216541074 creator A5039977865 @default.
• W3216541074 creator A5044028607 @default.
• W3216541074 creator A5047773810 @default.
• W3216541074 creator A5048042745 @default.
• W3216541074 creator A5054146130 @default.
• W3216541074 creator A5054410446 @default.
• W3216541074 creator A5055169632 @default.
• W3216541074 creator A5058100068 @default.
• W3216541074 creator A5065845532 @default.
• W3216541074 creator A5069085930 @default.
• W3216541074 creator A5073404132 @default.
• W3216541074 creator A5076092828 @default.
• W3216541074 creator A5081671715 @default.
• W3216541074 creator A5084412014 @default.
• W3216541074 creator A5090256845 @default.
• W3216541074 date "2021-11-30" @default.
• W3216541074 modified "2023-10-17" @default.
• W3216541074 title "Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial" @default.
• W3216541074 cites W1574906247 @default.
• W3216541074 cites W2006434907 @default.
• W3216541074 cites W2020526475 @default.
• W3216541074 cites W2051646320 @default.
• W3216541074 cites W2061410297 @default.
• W3216541074 cites W2094585602 @default.
• W3216541074 cites W2114214167 @default.
• W3216541074 cites W2121451738 @default.
• W3216541074 cites W2138238488 @default.
• W3216541074 cites W2142640478 @default.
• W3216541074 cites W2162249417 @default.
• W3216541074 cites W2409181187 @default.
• W3216541074 cites W2469854628 @default.
• W3216541074 cites W2804714053 @default.
• W3216541074 cites W2887567733 @default.
• W3216541074 cites W2921112006 @default.
• W3216541074 cites W2937132453 @default.
• W3216541074 cites W2955647585 @default.
• W3216541074 cites W3007596355 @default.
• W3216541074 cites W3021040384 @default.
• W3216541074 cites W3095633432 @default.
• W3216541074 cites W3102461696 @default.
• W3216541074 cites W3116092871 @default.
• W3216541074 cites W3143388833 @default.
• W3216541074 cites W3171831654 @default.
• W3216541074 cites W3173237936 @default.
• W3216541074 cites W3202897054 @default.
• W3216541074 cites W4211043869 @default.
• W3216541074 cites W4238103798 @default.
• W3216541074 doi "https://doi.org/10.1136/svn-2021-001070" @default.
• W3216541074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34848566" @default.
• W3216541074 hasPublicationYear "2021" @default.
• W3216541074 type Work @default.
• W3216541074 sameAs 3216541074 @default.
• W3216541074 citedByCount "9" @default.
• W3216541074 countsByYear W32165410742022 @default.
• W3216541074 countsByYear W32165410742023 @default.
• W3216541074 crossrefType "journal-article" @default.
• W3216541074 hasAuthorship W3216541074A5002655528 @default.
• W3216541074 hasAuthorship W3216541074A5003098121 @default.
• W3216541074 hasAuthorship W3216541074A5010123141 @default.
• W3216541074 hasAuthorship W3216541074A5013597842 @default.
• W3216541074 hasAuthorship W3216541074A5015105927 @default.
• W3216541074 hasAuthorship W3216541074A5016876268 @default.
• W3216541074 hasAuthorship W3216541074A5018029121 @default.
• W3216541074 hasAuthorship W3216541074A5018605276 @default.
• W3216541074 hasAuthorship W3216541074A5019133381 @default.
• W3216541074 hasAuthorship W3216541074A5020883910 @default.
• W3216541074 hasAuthorship W3216541074A5023847142 @default.
• W3216541074 hasAuthorship W3216541074A5024784197 @default.
• W3216541074 hasAuthorship W3216541074A5025718857 @default.
• W3216541074 hasAuthorship W3216541074A5028774301 @default.
• W3216541074 hasAuthorship W3216541074A5034143823 @default.
• W3216541074 hasAuthorship W3216541074A5035996984 @default.
• W3216541074 hasAuthorship W3216541074A5036319128 @default.
• W3216541074 hasAuthorship W3216541074A5037141792 @default.
• W3216541074 hasAuthorship W3216541074A5037210013 @default.

• next